Cabaletta Bio Is Maintained at Buy by Citigroup

Cabaletta Bio Is Maintained at Buy by Citigroup

Dow JonesApr 4 23:57

Citigroup Maintains Buy on Cabaletta Bio, Raises Price Target to $30

Citigroup analyst Samantha Semenkow maintains Cabaletta Bio with a Buy and raises the price target from $26 to $30.

Analyst UpgradesApr 4 23:47

Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Cabaletta Bio (CABA)

TipRanksApr 4 17:20

Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), HilleVax, Inc (HLVX) and Cabaletta Bio (CABA)

TipRanksMar 26 10:10

Cabaletta Bio Issued ID#NCT06328777 For Phase 1/2 Open-Label Study To Evaluate The Safety And Efficacy Of CABA-201, A CD19-CAR T Cell Therapy, In Subjects With Systemic Sclerosis Posted To Clinical Trials Website On 2024-03-25; Study Is Not Yet Recruiting

Inclusion Criteria: Age ≥18 and ≤70A clinical diagnosis of SSc, based on the 2013 American College of Rheumatology and European League Against Rheumatism classification criteria.Early active diseaseEv

BenzingaMar 25 22:25

Cabaletta Bio Inc (CABA) Earnings: Aligns With EPS Projections, Forecasts Extended Cash Runway

Yahoo FinanceMar 23 17:31